Free Trial
NASDAQ:KRON

Kronos Bio Q2 2024 Earnings Report

Kronos Bio EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Kronos Bio Revenue Results

Actual Revenue
$2.69 million
Expected Revenue
$1.75 million
Beat/Miss
Beat by +$940.00 thousand
YoY Revenue Growth
N/A

Kronos Bio Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Wednesday, August 7, 2024
Conference Call Time
6:00PM ET

Kronos Bio Earnings Headlines

Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors.tc pixel
Kronos Bio sends Cambridge lab space back to market
See More Kronos Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kronos Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kronos Bio and other key companies, straight to your email.

About Kronos Bio

Kronos Bio (NASDAQ:KRON), a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

View Kronos Bio Profile

More Earnings Resources from MarketBeat